MINNEAPOLIS, Sept. 30, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela” or the “Company”), a medical stage firm growing disruptive therapeutics for the therapy of sufferers with pressing unmet medical wants, immediately introduced the pricing of a public providing of (i) 20,100,000 shares of its frequent inventory (or pre-funded warrants in lieu thereof) and (ii) warrants to buy as much as 30,150,000 shares of its frequent inventory (the “Public Warrants”) at a purchase order value of $0.30 per share and related Public Warrant. The Public Warrants can have an train value of $0.30 per share, are exercisable upon issuance, and can expire 5 years following the date of issuance. The providing is predicted to shut on or about October 4, 2022, topic to customary closing situations.
Roth Capital Partners, LLC is appearing as lead placement agent, Craig-Hallum Capital Group LLC and Maxim Group LLC are every appearing as co-placement agent of the providing.
Gross proceeds, earlier than deducting placement agent charges and commissions and providing bills are anticipated to be roughly $6 million. The Company intends to make use of the web proceeds from the proposed providing for the continued medical growth of its product candidates ivospemin (SBP-101) and eflornithine (CPP-1X), working capital, business growth and different normal company functions, which can embrace reimbursement of debt.
The securities described above are being provided pursuant to a registration assertion on Form S-1 (File No. 333-267000), as amended, that was declared efficient by the U.S. Securities and Exchange Commission (“SEC”), on September 29, 2022. Copies of the accompanying prospectus referring to and describing the phrases of the providing could also be obtained, when obtainable, on the SEC’s web site at www.sec.gov or by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660 or by e mail at [email protected].
This press launch doesn’t and shall not represent a suggestion to promote or the solicitation of a suggestion to purchase any securities, nor shall there be any sale of these securities in any state or different jurisdiction through which such provide, solicitation or sale can be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or different jurisdiction. Any provide, if in any respect, shall be made solely by means of a prospectus, together with a prospectus complement, forming an element of the efficient registration assertion.
About our Pipeline
The pipeline consists of belongings presently in medical trials with an preliminary deal with familial adenomatous polyposis (FAP), first-line metastatic pancreatic most cancers, neoadjuvant pancreatic most cancers, colorectal most cancers prevention and ovarian most cancers. The mixed growth packages have a gentle cadence of catalysts with packages starting from pre-clinical to registration research.
SBP-101 Ivospemin
Ivospemin is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an noticed excessive affinity of the compound for pancreatic ductal adenocarcinoma and different tumors. It has proven indicators of tumor progress inhibition in medical research of metastatic pancreatic most cancers sufferers, demonstrating a median total survival (OS) of 14.6 months and an goal response charge (ORR) of 48%, each exceeding what’s typical for the usual of care of gemcitabine + nab-paclitaxel suggesting potential complementary exercise with the prevailing FDA-approved commonplace chemotherapy routine. In information evaluated from medical research up to now, ivospemin has not proven exacerbation of bone marrow suppression and peripheral neuropathy, which could be chemotherapy-related opposed occasions. Serious visible opposed occasions have been evaluated and sufferers with a historical past of retinopathy or in danger of retinal detachment shall be excluded from future SBP-101 research. The security information and PMI profile noticed within the earlier Panbela-sponsored medical trials present help for continued analysis of ivospemin within the ASPIRE trial. For extra data, please go to https://clinicaltrials.gov/ct2/show/NCT03412799 .
Flynpovi ™
Flynpovi is a mixture of CPP-1X (eflornithine) and sulindac with a twin mechanism inhibiting polyamine synthesis and enhance polyamine export and catabolism. In a Phase 3 medical trial in sufferers with sporadic giant bowel polyps, the mixture prevented > 90% subsequent pre-cancerous sporadic adenomas versus placebo. Focusing on FAP sufferers with decrease gastrointestinal tract anatomy within the latest Phase 3 trial evaluating Flynpovi to single agent eflornithine and single agent sulindac, FAP sufferers with decrease GI anatomy (sufferers with an intact colon, retained rectum or surgical pouch), Flynpovi confirmed statistically important profit in comparison with each single brokers (p≤0.02) in delaying surgical occasions within the decrease GI for as much as 4 years. The security profile for Flynpovi didn’t considerably differ from the only brokers and helps the continued analysis of Flynpovi for FAP.
CPP-1X
CPP-1X (eflornithine) is being developed as a single agent pill or excessive dose energy sachet for a number of indications together with prevention of gastric most cancers, therapy of neuroblastoma and up to date onset Type 1 diabetes. Preclinical research in addition to Phase 1 or Phase 2 investigator-initiated trials recommend that CPP-1X therapy could also be well-tolerated and has potential exercise.
About Panbela
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical firm growing disruptive therapeutics for sufferers with pressing unmet medical wants. Panbela’s lead belongings are Ivospemin (SBP-101) and Flynpovi. Further data could be discovered at www.panbela.com. Panbela’s frequent inventory is listed on The Nasdaq Stock Market LLC beneath the image “PBLA”.
Cautionary Statement Regarding Forward-Looking Statements
This press launch comprises “forward-looking statements,” together with inside the that means of the Private Securities Litigation Reform Act of 1995. Forward-looking statements could be identified by phrases similar to: “anticipate,” “design,” “expect,” “intend,” “may,” “plan,” “scheduled,” and “will.” Examples of forward-looking statements embrace statements we make concerning outcomes of collaborations with third events and future research. All statements aside from statements of historic truth are statements that must be deemed forward-looking statements. Forward-looking statements are neither historic info nor assurances of future efficiency. Instead, they’re primarily based solely on our present beliefs, expectations, and assumptions concerning the long run of our business, future plans and techniques, projections, anticipated occasions and traits, the economy and different future situations. Because forward-looking statements relate to the long run, they’re topic to inherent uncertainties, dangers and adjustments in circumstances which are tough to foretell and lots of of that are exterior of our management. Our precise outcomes and monetary situation could differ materially and adversely from the forward-looking statements. Therefore, you shouldn’t depend on any of these forward-looking statements. Important elements that might trigger our precise outcomes and monetary situation to vary materially from these indicated within the forward-looking statements embrace, amongst others, the next: (i) our skill to acquire extra funding to execute our business and medical growth plans; (ii) progress and success of our medical growth program; (iii) the impression of the present COVID-19 pandemic on our skill to conduct our medical trials; (iv) our skill to exhibit the security and effectiveness of our product candidates: ivospemin(SBP-101) and eflornithine (CPP-1X) (v) our reliance on a 3rd social gathering for the execution of the registration trial for our product candidate Flynpovi; (vi) our skill to acquire regulatory approvals for our product candidates, SBP-101 and CPP-1X within the United States, the European Union or different worldwide markets; (vii) the market acceptance and stage of future gross sales of our product candidates, SBP-101 and CPP-1X; (viii) the associated fee and delays in product growth that will end result from adjustments in regulatory oversight relevant to our product candidates, SBP-101 and CPP-1X; (ix) the speed of progress in establishing reimbursement preparations with third-party payors; (x) the impact of competing technological and market developments; (xi) the prices concerned in submitting and prosecuting patent purposes and implementing or defending patent claims; and (xi) such different elements as mentioned in Part I, Item 1A beneath the caption “Risk Factors” in our most up-to-date Annual Report on Form 10-Ok, any extra dangers introduced in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-Ok. Any forward-looking assertion made by us on this press launch is predicated on data presently obtainable to us and speaks solely as of the date on which it’s made. We undertake no obligation to publicly replace any forward-looking assertion or the reason why precise outcomes would differ from these anticipated in any such forward-looking assertion, whether or not written or oral, whether or not as a end result of new data, future developments or in any other case.
Contact Information:
Investors:
James Carbonara
Hayden IR
(646) 755-7412
[email protected]
Media:
Tammy Groene
Panbela Therapeutics, Inc.
(952) 479-1196
[email protected]
